Hemanext Inc (AKA: NHSI~New Health Sciences Inc) Profile last edited on: 10/31/2023
CAGE: 47HT2
UEI: CC3QRDB7EYX7
Business Identifier: Anaerobic storage technology extending shelf life of refrigerated red blood cells 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
99 Hayden Avenue Building B Suite 620
Lexington, MA 02421
Lexington, MA 02421
| (781) 301-7474 |
| info@hemanext.com |
| www.hemanext.com |
Location: Multiple
Congr. District: 05
County: Middlesex
Congr. District: 05
County: Middlesex
Public Profile
A medical technology company offering a blood processing, storage, and transfusion solution, Hemanext was formerly (until Oct 2017) doing business as New Health Systems Inc, (NHSI) with facilities in MA and in MD. With corporate HQ now in Lexington MA and manufacturing operations in Avon, MA, the firm is structured around achieving radical improvements in the quality, safety, efficacy and cost of transfusion therapy. An innovator in blood processing and storage technology (two primary areas of focus) the firm is working on (1) Hemanext an innovative storage system for red blood cells and whole blood that is designed to preserve their efficacy and safety characteristics during storage, as well as to extend their potential storage life and on (2) MVA (MicroVascular Analyzer) - a novel test and measurement system that provides both researchers and clinicians with a precise, highly sensitive measure of RBC deformability in a simulated capillary network using very small samples.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
75-99Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 2 | NIH | $1,495,035 | |
| Project Title: An Additive Solution Optimized for Anaerobic (Hypoxic) RBC Storage to Minimize Storage Lesion Development | ||||
| 2018 | 2 | NIH | $2,969,758 | |
| Project Title: Regulatory Approval & Commercialization of an RBC Processing and Storage System to Improve Transfusion Therapy by Minimizing Oxidative Damage to RBC During Storage | ||||
| 2013 | 1 | NIH | $195,127 | |
| Project Title: RBC Storage System to Minimize Storage Lesions | ||||
| 2013 | 1 | NIH | $195,127 | |
| Project Title: Sbir Topic 74; Phase I; Rbc Storage System to Minimize Storage Lesions | ||||
| 2010 | 2 | NIH | $2,027,436 | |
| Project Title: Anaerobically stored red blood cells with extended shelf-life | ||||
Key People / Management
Martin Cannon -- Founder, President and CEO
Joseph Barrett -- Vice President General Counsel and Corporate Secretary
Michael Bavonese -- Director, Finance & Administration
Vic Dolecekvice -- Vice President of Product Development and Operations
Andrew Dunham -- Chief Technology Officer
Robert Haime -- Vice President of Commercial Operations
Heather Keith -- Director, WebTCD Sales & Marketing
Paul Lea
Lynn Mallett -- Chief Financial Officer
Eric Newman -- Chief Financial Officer
Laurel Omert -- Chief Medical Officer
Tony Pare -- Chief Commercial Officer
Ronald Pelletier -- Senior Manager, Senior Manager, Accounting Manager
Clair Strohl -- Director, Hemanext Product Development
Steve Urdahl -- Director of Business Development
Tatsuro Yoshida -- Director, Research and Development, Hemanext
Joseph Barrett -- Vice President General Counsel and Corporate Secretary
Michael Bavonese -- Director, Finance & Administration
Vic Dolecekvice -- Vice President of Product Development and Operations
Andrew Dunham -- Chief Technology Officer
Robert Haime -- Vice President of Commercial Operations
Heather Keith -- Director, WebTCD Sales & Marketing
Paul Lea
Lynn Mallett -- Chief Financial Officer
Eric Newman -- Chief Financial Officer
Laurel Omert -- Chief Medical Officer
Tony Pare -- Chief Commercial Officer
Ronald Pelletier -- Senior Manager, Senior Manager, Accounting Manager
Clair Strohl -- Director, Hemanext Product Development
Steve Urdahl -- Director of Business Development
Tatsuro Yoshida -- Director, Research and Development, Hemanext
